Omixon Founder, Attila Bérces Returns as CEO, Aims to Roll-Out New Products

20/04/2020

We are happy to announce that Omixon’s founder and chairman Dr. Attila Bérces returns as CEO. Outgoing CEO Dr. Peter Meintjes led the early commercialization of Omixon’s flagship product Holotype HLA since 2014 before stepping into the CEO role in 2017. In concert between the incoming and outgoing CEOs,...

Webinar – HLA Typing Uses in Research. How is HLA Explore Used to Facilitate it?

20/03/2020

Join us for a Webinar on Tuesday, April 7 with Efi Melista (Head of Product, Omixon) who will be talking about the uses of HLA typing in research and population studies, and how Omixon’s HLA Explore can facilitate it. Examples in disease associations, pharmacogenetics, drug sensitivities and overall population...

Do You Know What it Takes to CE Mark an HLA Typing Product?

16/03/2020

Abstract presentation by Omixon’s Senior Technical Lead Assay R&D, Dr. Gergely Tölgyesi, from the latest 14th East-West Immunogenetics Conference (Budapest, Hungary). Abstract: European transplantation laboratories require the use of CE-marked HLA typing products for diagnostic purposes. The CE mark (“Conformité Européenne”, French for European conformity) is a symbol that...

EWIC 2020 Conference in Budapest

13/03/2020

The East-West Immunogenetics Conference is one of the most well-known events in East-Central Europe and its purpose is to connect experts from the East-European countries with the Western countries. This tradition was initiated in 2006 in Prague, Czech Republic, and since then its popularity is constantly increasing. This year...

Haplotyping Hungarian Paediatric ALL HLA-class II Genes Using NGS

10/03/2020

Abstract presentation by Omixon’s Medior Bioinformatician, Lívia Lázár from the latest 14th East-West Immunogenetics Conference (Budapest, Hungary). Abstract: As a result of an ongoing effort between multiple Hungarian departments of pediatric haematology, 576 patients’ peripheral blood was collected for meta-analysis between 1990 and 2012. The 576 samples were...